45 PROLONGING THE FIRST CELL CYCLE IN NUCLEAR TRANSFER BOVINE EMBRYOS DOES NOT INCREASE CLONING EFFICIENCY
R. G. Blaza A , J. E. Oliver A , B. Oback A and D. N. Wells AAgResearch, Hamilton, New Zealand
Reproduction, Fertility and Development 22(1) 180-180 https://doi.org/10.1071/RDv22n1Ab45
Published: 8 December 2009
Abstract
We hypothesized that reprogramming a somatic cell following NT is a time-dependent process that can be improved by artificially prolonging the first cell cycle of the cloned embryo. Eleven candidate drugs were initially screened for their ability to reversibly delay the onset of the first cleavage in bovine parthenotes without affecting subsequent in vitro embryo development. After identifying the cyclin-dependent kinase inhibitor butyrolactone-1 (BLT1; BIOMOL International, Plymouth Meeting, PA, USA) as a suitable candidate, we determined its optimal concentration and exposure time. We then performed zona-free bovine NT with serum-starved male skin fibroblasts. Commencing 10 h after the start of IVC, reconstructed 1-cell embryos were treated with either 200 μM BLT1 or 0.4% DMSO in SOF culture medium for 8 to 11 h. After thorough washing, cleavage rates were recorded and culture continued until Day 7. Labeling with 5-bromo-2-deoxyuridine (BrdU) was used to determine DNA replication during the first cell cycle. Some embryos were also transferred singularly to recipient cows. Embryo development was analyzed by a generalized linear model with binomial variation and pregnancy rates by Fisher’s exact test. At 0, 2, 4, 6, and 10 h after the start of IVC, 0% (0/28), 8% (5/61), 67% (39/58), 90% (54/60), and 100% (16/16), respectively, of NT reconstructs had incorporated BrdU, indicating that all 1-cell NT embryos were in S-phase at the start of treatment. After 8 to 11 h of incubation in BLT1, only 28% (119/429) of NT embryos had cleaved, compared with 93% of DMSO-treated controls (297/319). After removing BLT1 in those embryos arrested at the 1-cell-stage, there was no BrdU incorporation over the subsequent 1 h (0/17), embryos entered mitosis and by 4 h, 90% had cleaved (86/96). Thus, BLT1-arrested embryos were at a post-replicative stage prior to M-phase. Rates of in vitro embryo development on Day 7, from late morula to expanded blastocyst stages, of either grade 1-3 or grade 1-2 quality, in the BLT1 treatment were not different compared with controls (129/275 = 47% v. 151/309 = 49% and 33% v. 33%, respectively). Nuclei counts in expanded blastocysts from the BLT1 treatment were not significantly different than controls (109 v. 121, n = 31). Embryo survival on Day 35 of pregnancy and for calves to 1 month ofage was also not different between BLT1 and control treatments (13/31 = 42% v. 12/29 = 41% and 6% v. 10%, respectively). In conclusion, treating 1-cell NT embryos in S-phase for 8 to 11 h with 200 μM BLT1 arrested embryos in G2 and delayed cleavage by approximately 6 h. Cell cycle arrest was fully reversible after drug withdrawal, with rates of cleavage and in vitro development comparable to that of controls. The prolongation of the first cell cycle in bovine NT embryos using this method did not, however, increase cloning efficiency. Arrest for longer periods, at other stages of the cell cycle, and using alternative reagents may be beneficial.